Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer.
作者信息
Limaye Sewanti, Kumar Prashant, Pragya Ramya, Sambath Janani, Patil Darshana, Srinivasan Ajay, Apurva Sachin, Srivastava Navin, Patil Sanket, Patil Revati, Datta Vineet, Akolkar Dadasaheb, Datar Rajan
机构信息
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India.
Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
出版信息
Oncotarget. 2022 Aug 4;13:982. doi: 10.18632/oncotarget.28262.
Abstract
摘要
相似文献
1
Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer.
Oncotarget. 2022 Aug 4;13:982. doi: 10.18632/oncotarget.28262.
2
A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer.
Oncotarget. 2020 Nov 17;11(46):4358-4363. doi: 10.18632/oncotarget.27809.
3
Response to trametinib in recurrent low-grade serous ovarian cancer with mutation: A case report.
Gynecol Oncol Rep. 2019 Jan 31;28:26-28. doi: 10.1016/j.gore.2019.01.007. eCollection 2019 May.
4
Laparoscopic Resection of a High Grade Serous Ovarian Cancer that Recurred at the Vaginal Stump with Extensive Pelvic Adhesions after Complete Surgical Staging.
J Minim Invasive Gynecol. 2022 Mar;29(3):343-344. doi: 10.1016/j.jmig.2021.11.019. Epub 2021 Dec 3.
5
Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum.
Gynecol Oncol Rep. 2020 Nov 2;34:100670. doi: 10.1016/j.gore.2020.100670. eCollection 2020 Nov.
7
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.
8
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).
Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May.
9
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecol Oncol. 2009 Jul;114(1):48-52. doi: 10.1016/j.ygyno.2009.03.001. Epub 2009 Apr 10.
10
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
Gynecol Oncol. 2012 Jan;124(1):142-7. doi: 10.1016/j.ygyno.2011.09.004. Epub 2011 Oct 15.
引用本文的文献
1
Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors.
Biomedicines. 2024 Apr 25;12(5):957. doi: 10.3390/biomedicines12050957.
Zotero 插件